What We're Reading: Page 58
Industry reads hand-picked by our editors
Jan 30, 2024
Jan 29, 2024
-
The New York Times
Buried in Wegovy Costs, North Carolina Will Stop Paying for Obesity Drugs
-
Science
Alzheimer’s disease may have been transmitted in now-banned hormone treatments
-
Stat
Scientific sleuth shook Dana-Farber from a small town in Wales
-
Bloomberg
Dyne Therapeutics Weigh Options After Takeover Interest
Jan 26, 2024
-
Bloomberg
How a Lucky Break Fueled Eli Lilly’s $600 Billion Weight-Loss Empire
-
The Bureau of Investigative Journalism
‘The response defies belief’: year of inaction leaves children at risk from bad cancer drugs
-
Wired
6 Deaf Children Can Now Hear After a Single Injection
-
PharmaVoice
‘1 plus 1 equals 3’ — the co-CEO model in pharma
Jan 25, 2024
-
Reuters
US pharmacy benefit lobby group ramps up spending as lawmakers close in
-
The New England Journal of Medicine
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
-
Bloomberg
Startup Founders Ghost Investors to Avoid Dreaded Down Round
-
Undark
How the World’s Deadliest Crises Go Unseen
Jan 24, 2024
Jan 23, 2024
-
Axios
Unlikely political allies take on drugmakers’ patent tactics
-
Stat
Dana Farber says 6 studies to be retracted and 31 corrected
-
The Wall Street Journal
Obesity Drugs Lead to Muscle Loss—Pharma Companies Want to Fix That
-
Reuters
J&J profit edges past Street view after deals delay Stelara competition
Jan 22, 2024
-
MIT Technology Review
Scientists are finding signals of long covid in blood. They could lead to new treatments.
-
C&EN
Biomanufacturers will pursue small projects to weather the economic storm
-
Reuters
US FDA adds ‘boxed warning’ for Amgen’s bone loss drug Prolia
-
Bloomberg
Evotec Says Former CEO Failed to Report Stock Trades on Time
Previous
